"Insulin, Long-Acting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
| Descriptor ID |
D049528
|
| MeSH Number(s) |
D06.472.699.587.200.300 D12.644.548.586.200.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Insulin, Long-Acting".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Long-Acting".
This graph shows the total number of publications written about "Insulin, Long-Acting" by people in this website by year, and whether "Insulin, Long-Acting" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 2 | 5 |
| 2018 | 6 | 1 | 7 |
| 2019 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin, Long-Acting" by people in Profiles.
-
The impact of strict COVID-19 lockdown in Spain on glycemic profiles in patients with type 1 Diabetes prone to hypoglycemia using standalone continuous glucose monitoring. Diabetes Res Clin Pract. 2020 Sep; 167:108354.
-
Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. J Clin Endocrinol Metab. 2019 12 01; 104(12):5977-5990.
-
IDegLira: combining efficacy, durability, and convenience? Lancet Diabetes Endocrinol. 2019 08; 7(8):584-585.
-
[Basal insulin degludec (Tresiba®)]. Rev Med Liege. 2019 Apr; 74(4):226-232.
-
Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes. Drugs. 2019 Feb; 79(2):173-186.
-
[Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)]. Rev Med Liege. 2018 Oct; 73(10):526-532.
-
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018 10; 41(10):2147-2154.
-
Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest. 2019 Mar; 42(3):345-349.
-
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. Diabetes Obes Metab. 2018 09; 20(9):2148-2158.
-
Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp). Adv Ther. 2018 07; 35(7):928-936.